<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21120" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Endothelial Derived Relaxation Factor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pirahanchi</surname>
            <given-names>Yasaman</given-names>
          </name>
          <aff>California Northstate College Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marsidi</surname>
            <given-names>Jennifer L.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brown</surname>
            <given-names>Kristen N.</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasaman Pirahanchi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jennifer Marsidi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristen Brown declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21120.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Endothelium-derived relaxing factor (EDRF) is an endogenous vasodilator that endothelial cells produce and subsequently release in response to various changes in normal physiologic as well as pathophysiologic changes. EDRF causes vascular smooth muscle to relax, as it activates soluble guanylate cyclase and subsequently increases cyclic guanylate monophosphate in vascular smooth muscle. EDRF is structurally in the form of nitric oxide (NO) or a compound that contains nitrogen oxide. EDRF is formed from L-arginine by an enzyme that is&#x000a0;dependant on calcium-calmodulin and NADPH. EDRF serves as an inhibitor of aggregation and adhesion of platelets and is a vasodilator. EDRF also serves as a second messenger for guanylyl cyclase activation and cyclic GMP production. EDRF&#x02019;s function, pathophysiology, and it's clinical significance will be the subject in this review.<xref ref-type="bibr" rid="article-21120.r1">[1]</xref></p>
      </sec>
      <sec id="article-21120.s2" sec-type="Function">
        <title>Function</title>
        <p>All vascular beds, small and large vessels contain EDRF; this is true for many species. EDRF acts directly on vascular smooth muscle to invoke endogenous vasodilation and inhibiting sympathetic vasoconstriction.<xref ref-type="bibr" rid="article-21120.r2">[2]</xref>&#x000a0;It is the active particle in nitrovasodilating agents such as nitrates and nitroglycerin.&#x000a0;EDRF functions as a second messenger for activation of guanylyl cyclase and the production of cyclic GMP for cells in cardiovascular tissue, respiratory and renal epithelium, macrophages, neurons of the cerebellum, and adrenocytes.<xref ref-type="bibr" rid="article-21120.r3">[3]</xref></p>
        <p>EDRF serves as nitric oxide that functions through activating soluble guanylyl cyclase. Endothelial cell membranes contain an enzyme called endothelial nitric oxide synthase which produces nitric oxide, which then binds to soluble guanylyl cyclase in smooth muscle cells. This binding triggers a cell signaling cascade, ultimately leading to&#x000a0;arteriole vasodilation. This process of endogenous nitric oxide production physiologically modulates blood flow and vasomotion.<xref ref-type="bibr" rid="article-21120.r4">[4]</xref></p>
        <p>It also has&#x000a0;antiplatelet properties&#x000a0;by inhibiting platelet adhesion and platelet aggregation. The&#x000a0;decrease in platelet activation directly&#x000a0;leads to an anti-thrombotic effect.<xref ref-type="bibr" rid="article-21120.r5">[5]</xref> NO also has anti-inflammatory properties by intrinsic inhibition of leukocytes adhesion to the endothelium.<xref ref-type="bibr" rid="article-21120.r6">[6]</xref>&#x000a0;It is this antithrombotic effect along with arteriole vasodilation that has had such a huge impact on the clinical arena.&#x000a0;</p>
      </sec>
      <sec id="article-21120.s3" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pathophysiologic conditions affected by EDRF dysfunction include an increase in monocyte and platelet adhesion to the endothelium, myocardial infarction, atherosclerosis, and stroke. This activity may be due to increased peripheral vascular tone caused by increased superoxide radical inactivation of NO or impaired NO synthesis. For example, the first step to the atherosclerotic process is endothelial dysfunction.<xref ref-type="bibr" rid="article-21120.r7">[7]</xref></p>
        <p>The quiescent endothelial cell in its normal state is attached&#x000a0;to the endothelial cell surface and attached to the&#x000a0;basement membrane. The endothelial cell has protective mechanisms against endothelial glycocalyx dysfunction and endothelial cell dysfunction. These protective mechanisms&#x000a0;include a&#x000a0;functional glycocalyx which&#x000a0;coats the external surface of the plasma membrane in a composition of glycoprotein and glycolipid and several micro as well as macro physiologic responses to stress.</p>
        <p>Type 1 endothelial activation, type 2 endothelial activation, endothelial apoptosis, and endothelial necrosis, all lead to endothelial dysfunction.&#x000a0;Type 1 endothelial activation occurs almost immediately and does not require gene transcription or de novo protein synthesis. Type 2 endothelial activation can occur over a longer period, taking hours, days, or even months in some cases. In contrast to type 1 endothelial dysfunction, type 2 endothelial dysfunction requires gene transcription and de novo protein synthesis, thus requiring a longer period to progress. If endothelial activation is uncontrolled, type 2 endothelial activation can lead to endothelial apoptosis. Chronic endothelial activation can then lead to endothelial necrosis. &#x000a0;This is significant in cardiorenal syndrome, where endothelial dysfunction may serve as an intersection between renal dysfunction and cardiac dysfunction.<xref ref-type="bibr" rid="article-21120.r8">[8]</xref></p>
        <p>Endothelial cell activation can lead to reversible endothelial dysfunction. In this case, target treatment aims to restore normal endothelial cell function and to stop the reversible endothelial dysfunction. However, if the reversible endothelial dysfunction progresses without treatment, it can lead to endothelial apoptosis and endothelial necrosis. Both endothelial apoptosis and necrosis lead to irreversible endothelial dysfunction. In this case, target treatment cannot restore normal endothelial cell function nor stop reversible endothelial dysfunction.<xref ref-type="bibr" rid="article-21120.r8">[8]</xref></p>
      </sec>
      <sec id="article-21120.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Cardiovascular disease is among the leading causes of death today. Atherosclerosis and hypertension are major risk factors for cardiovascular disease. Endothelial dysfunction also plays a crucial role in atherosclerotic disease and hypertension. Dysfunction in&#x000a0;EDRF can lead to an increase in platelet adhesion which subsequently&#x000a0;increases the risk of a prothrombotic state. Dysfunction in the relaxation factor also leads to paradoxical&#x000a0;vasoconstriction. As hypertension worsens, the increased intravascular pressures may lead to further endothelial damage. Both atherosclerotic disease and hypertension put patients at risk for more life-threatening conditions such as myocardial infarction and/or stroke.</p>
        <p>Interventions that aim to treat endothelial dysfunction, target the underlying risk factors that cause endothelial damage. For example, medications such as ACE inhibitors and calcium channel antagonists treat hypertension, and lipid-lowering agents are used for hypercholesterolemia. Lifestyle modification also plays a large role in treatment. Smoking cessation helps to decrease the possible ramifications of cigarette smoking on endothelial dysfunction, and an increase in physical activity is used to prevent endothelial dysfunction due to a sedentary lifestyle. Chronic conditions that can lead to endothelial dysfunction can also be treated, such as increasing control of abnormal metabolic conditions in diabetes mellitus and estrogen replacement therapy in menopause. Pharmacologic agents that can achieve vascular protection in addition to their primary therapeutic indications are ACE inhibitors and HMG COA reductase inhibitors. All of these interventions help induce positive changes in the endothelium due to inhibition of vasoconstriction, promotion of vasorelaxation, decreased free radical production, or other protective mechanisms against endothelial injury.<xref ref-type="bibr" rid="article-21120.r7">[7]</xref></p>
        <p>Stimulators of EDRF release include insulin and adiponectin. Chronic NO release by endothelial cells can be upregulated by dietary factors, estrogen, and exercise, and downregulated by oxidative stress, pollution, smoking, and oxidized low-density lipoproteins. NO release is also decreased with aging and in vascular diseases such as hypertension and diabetes. With impaired nitric oxide production, such as by oxidative stress, spontaneous hypertension, aging, and diabetes, this exacerbates endothelium-dependent contractions, and can contribute to decreased endothelium-dependent vasodilation in patients with essential hypertension or diabetes, as well as aging patients. Endothelin 1 can also contribute to endothelial dysfunction and vascular dysfunction. Also, under conditions of hypoxia, nitric oxide can cause unbalanced activation of soluble guanylyl cyclase such that cyclic inosine monophosphate (cIMP) production increases, instead of cGMP. &#x000a0;This increased cIMP can then lead to contraction of underlying vascular smooth muscle, instead of relaxation.<xref ref-type="bibr" rid="article-21120.r9">[9]</xref></p>
        <p>Ischemic diseases with impaired endothelial function have impaired EDRF formation and release into the vasculature include hypercholesterolemia, atherosclerosis, hypertension-induced vascular damage, diabetes, reperfusion damage, coronary spasm, and subarachnoid hemorrhage-induced vasospasm. In these ischemic diseases, there is decreased EDRF release or hemoglobin or oxygen-derived radicals immediately inactivate the released NO before affecting the vasculature. Due to impaired EDRF release, there is&#x000a0;an increased vasoconstrictor tone, and this is exacerbated by insufficient receptor-stimulated or mechanical NO release in large feed arteries such as coronaries. This increased vasoconstrictor tone can cause inadequate blood supply which leads to ischemic damage.<xref ref-type="bibr" rid="article-21120.r10">[10]</xref></p>
      </sec>
      <sec id="article-21120.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21120&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21120">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21120/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21120">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21120.s6">
        <title>References</title>
        <ref id="article-21120.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliveira-Paula</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Lacchini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tanus-Santos</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms.</article-title>
            <source>Gene</source>
            <year>2016</year>
            <month>Jan</month>
            <day>10</day>
            <volume>575</volume>
            <issue>2 Pt 3</issue>
            <fpage>584</fpage>
            <page-range>584-99</page-range>
            <pub-id pub-id-type="pmid">26428312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanzinger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Czachurski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of sympathetic vasoconstriction is a major principle of vasodilation by nitric oxide in vivo.</article-title>
            <source>Circ Res</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1073</fpage>
            <page-range>1073-7</page-range>
            <pub-id pub-id-type="pmid">7955145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banin</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Bendhack</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Enhancing vascular relaxing effects of nitric oxide-donor ruthenium complexes.</article-title>
            <source>Future Med Chem</source>
            <year>2014</year>
            <month>May</month>
            <volume>6</volume>
            <issue>7</issue>
            <fpage>825</fpage>
            <page-range>825-38</page-range>
            <pub-id pub-id-type="pmid">24941875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Helms</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gladwin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Kim-Shapiro</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Erythrocytes and Vascular Function: Oxygen and Nitric Oxide.</article-title>
            <source>Front Physiol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>125</fpage>
            <pub-id pub-id-type="pmid">29520238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gambaryan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsikas</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A review and discussion of platelet nitric oxide and nitric oxide synthase: do blood platelets produce nitric oxide from L-arginine or nitrite?</article-title>
            <source>Amino Acids</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>9</issue>
            <fpage>1779</fpage>
            <page-range>1779-93</page-range>
            <pub-id pub-id-type="pmid">25929585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cockrell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laroux</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Jourd'heuil</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Van der Heyde</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grisham</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Role of inducible nitric oxide synthase in leukocyte extravasation in vivo.</article-title>
            <source>Biochem Biophys Res Commun</source>
            <year>1999</year>
            <month>Apr</month>
            <day>21</day>
            <volume>257</volume>
            <issue>3</issue>
            <fpage>684</fpage>
            <page-range>684-6</page-range>
            <pub-id pub-id-type="pmid">10208844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pesi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radenkovi&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grbovi&#x00107;</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Endothelial dysfunction: mechanisms of development and therapeutic options].</article-title>
            <source>Med Pregl</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>59</volume>
            <issue>7-8</issue>
            <fpage>335</fpage>
            <page-range>335-41</page-range>
            <pub-id pub-id-type="pmid">17140033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bottiglieri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McCullough</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome.</article-title>
            <source>Cardiorenal Med</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-117</page-range>
            <pub-id pub-id-type="pmid">28611784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanhoutte</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Shimokawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feletou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Endothelial dysfunction and vascular disease - a 30th anniversary update.</article-title>
            <source>Acta Physiol (Oxf)</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>219</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-96</page-range>
            <pub-id pub-id-type="pmid">26706498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21120.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bassenge</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical relevance of endothelium-derived relaxing factor (EDRF).</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1992</year>
            <volume>34 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>37S</fpage>
            <page-range>37S-42S</page-range>
            <pub-id pub-id-type="pmid">1633078</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
